Summit on Cancer Health Disparities (SCHD24)

Seattle, WA US
April 26, 2024 to April 28, 2024

This annual oncology conference, The Summit on Cancer Health Disparities (SCHD24), is one of the largest gatherings of cancer care professionals interested in cancer health disparities with a focus on achieving health equity. This year SCHD 2024 will feature lectures, panel discussions, and debates among leaders across the spectrum of cancer care delivery. This conference will bring together oncology professionals, cancer disparity researchers, and other stakeholders to discuss factors leading to cancer health disparities. A focus of the conference is to explore how these factors can be mitigated to optimize the outcomes of cancer patients. A distinctive feature of this conference is case-based discussions that will describe a problem, how it was solved, and the lessons learned.

SCHD 2024 is an accredited continuing education activity (CME activity) that will foster collaborative interdisciplinary interactions and partnerships to stimulate the development of new research and clinical practices that reduce cancer health disparities and improve outcomes of the diverse patient population.

Target Audience

  • Oncologists
  • Nurse Practitioners
  • Physician Assistants
  • Nurses
  • Pharmacists
  • Fellows/Residents
  • Researchers
  • Others interested in cancer disparities

Organizing Committee 

Program Director:

Dr. Binay Shah - Binaytara Foundation

Conference Co-Chairs:

Dr. Ana María López - Sidney Kimmel Cancer Center, Thomas Jefferson University

Dr. David Aboulafia - Virginia Mason Medical Center

Dr. Hannah Linden - University of Washington and Fred Hutchinson Cancer Center

Organizing Committee:

Dr. Martha Pritchett Mims - Baylor College of Medicine

Dr. Jorge Cortes - Georgia Cancer Center at Augusta University

Dr. Kamran Mirza - University of Michigan

Dr. Ishwaria Subbiah - Sarah Cannon Research Institute

Dr. Siddhartha Yadav - Mayo Clinic

Dr. Dan Milner - Union for International Cancer Control

Abstract Committee Co-Chairs:

Dr. Martha Pritchett Mims - Baylor College of Medicine

Dr. Darya Kizub - MD Anderson Cancer Center

Dr. Siddhartha Yadav - Mayo Clinic

Abstract Committee:

Dr. Ronan Hsieh - University of Washington and Fred Hutchinson Cancer Center

Dr. Srinivas Tantravahi - University of Utah Huntsman Cancer Institute

Dr. Manisha Bhattacharya - University of Pittsburgh Medical Center

Dr. Kamran Mirza - University of Michigan

Dr. Gregory Vidal - West Cancer Center

Dr. Ursa Brown-Glaberman - University of New Mexico Comprehensive Cancer Center

Dr. Fengting Yan - Swedish Cancer Institute

Dr. Dipesh Uprety - Karmanos Cancer Institute

Media and Publications Committee Co-Chairs

Dr. Ishwaria Subbiah - Sarah Cannon Research Institute

Dr. Kamran Mirza - University of Michigan

Dr. Umang Swami - University of Utah Huntsman Cancer Institute

Sponsorship Committee Chair:

Dr. Fengting Yan - Swedish Cancer Institute

HOTEL RESERVATION

Attendees and supporters of this meeting can book their hotel room at the Grand Hyatt Seattle at the discounted rate of $209/night + applicable taxes and fees. This rate is based on single occupancy and is valid three days before/after the meeting. The cut-off date is 04 April 2024. 

Click here to book your hotel room a the discounted rate.

Abstract Submission

Submit abstracts to present at the 2024 Summit on Cancer Health Disparities

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Identify drivers of cancer health disparities and review their impact on patients along the cancer continuum.
  2. Review barriers to using multidisciplinary cancer care and discuss evidence-based strategies to navigate these barriers to incorporate the new standards of care in managing patients with cancer.
  3. Discuss newer technologies and their impact on cancer health disparities. 
  4. Review the effectiveness of various interventional approaches and incorporate evidence-based strategies to minimize cancer health disparities in specific populations.
  5. Describe challenges and develop novel approaches, including technology utilization, to improve underrepresented communities' participation in clinical trials.
  6. Discuss the role of government policies and health care legislation in cancer health disparities and policy changes needed to improve access to cancer care.

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 14.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 14.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 14.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 14.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 14.25 Contact Hours.
Course opens: 
09/20/2023
Course expires: 
07/30/2024
Event starts: 
04/26/2024 - 8:00am PDT
Event ends: 
04/28/2024 - 4:00pm PDT
Cost:
$450.00

DAY 1 - APRIL 26, 2024

All times are listed in Pacific Time (PT)

07:00 AM – 08:00 AM: Registration, Breakfast, & Exhibits


08:00 AM – 08:15 AM  Welcome 


08:15 AM – 09:30 AM  Session 1: Understanding Disparities

Session Chairs: David Aboulafia, MD and Gita Suneja, MD, MS

08:15 AM – 08:20 AM  Introduction by Session Chairs

08:20 AM – 08:40 AM  Unpacking Disparities to Inform Action - Michele Andrasik, PhD

08:40 AM – 09:00 AM  Best Practices in Supporting LGBTQ+ Communities - Nakita Venus and Elle Brooks, MPH

09:00 AM – 09:30 AM  Panel Discussion - Alan Brownell; Derrick Mapp


09:30 AM – 10:00 AM  Break & Exhibits


10:00 AM – 11:30 AM  Session 2: Disparities: Access To Diagnostics and Care

Session Chairs: Mark Pegram, MD and Kamran M. Mirza, MD, PhD

10:00 AM – 10:15 AM  Pathology - Kamran M. Mirza, MD, PhD

10:15 AM – 10:30 AM  Precision Oncology - Siddhartha Devarakonda, MD

10:30 AM – 10:45 AM  GU Cancer - Ulka Vaishampayan, MD

10:45 AM – 11:00 AM  Hematologic Malignancies - Irum Khan, MD

11:00 AM – 11:15 AM  Lung Cancer - Nicholas P. Giustini, MD

11:15 AM – 11:30 AM  Panel Discussion 


11:30 AM – 12:15 PM  Session 3: Caring for the Carers: Diversity, Inclusion, and Professional Well-Being of the Global Community of Cancer Care Professionals

Session Chair: Ishwaria Subbiah, MD, MS, FASCO

11:30 AM – 11:45 AM  On Well-Being: Background and Rationale - Ana María López, MD, MPH, MACP

11:45 AM – 11:55 AM  On Well-Being Transitions: Training and Trainees - Carrie Fisher, DO

11:55 AM – 12:05 PM  An Experiential Session with 'the Best Medicine' - Carrie A. Horwitch, MD, MPH, MACP

12:05 PM – 12:15 PM  Panel Discussion


12:15 PM – 01:15 PM  Lunch & Exhibits


01:15 PM – 2:30 PM  Session 4: Integration of Technology into Cancer Care 

Session Chair: Manish Kohli, MD

01:15 PM – 01:35 PM  Artificial Intelligence to Facilitate Cancer Care - Joseph Finkelstein, MD, PhD, FAMIA, FACMI

01:35 PM – 01:50 PM  Digital Innovations in Cancer Care - Ana María López, MD, MPH, MACP

01:50 PM – 02:05 PM  Using Deep Learning and Patient-Reported Data to Predict Symptom Deterioration during a Chemotherapy Course - Aref Smiley, PhD

02:05 PM – 02:30 PM  Panel Discussion


02:30 PM – 02:45 PM  Break & Exhibits


02:45 PM – 04:15 PM  Session 5: Achieving Quality Through Value-Based Models for Cancer Care: Practical Solutions

Session Chair: Ana María López, MD, MPH, MACP

02:45 PM – 03:05 PM  ASCO Certified Patient-Centered Cancer Care Standards - Stephen S. Grubbs, MD, FASCO

03:05 PM – 03:20 PM  Value for Whom? How to Make Value for Patients - Barbara L. McAneny, MD

03:20 PM – 03:35 PM  Patient Perspectives on Cancer Care Delivery & Survivorship - Shelley Fuld Nasso, MPP

03:35 PM – 03:50 PM  Beyond the Measures: Advancing Quality in Healthcare - Michael Barr, MD, MBA, MACP, FRCP

03:50 PM – 04:15 PM  Panel Discussion


04:15 PM – 05:30 PM  Reception & Networking


**By invitation only**

06:00 PM – 09:00 PM  Career Connections Event and Argosy Cruise 

06:15 PM – 07:00 PM  Product Theater Sponsored by Janssen

Topic: Janssen Oncology Leading the Way with 5 Immunotherapies in Multiple Myeloma

Speaker: James R. Berenson, MD

07:00 PM – 07:30 PM  Dinner

07:30 PM – 08:15 PM  Career Connections Session

**This is a non-CME activity**

Sponsored by Genentech


 

DAY 2 - APRIL 27, 2024

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 09:30 AM  Session 6: Community Engagement

Session Chair: Martha Pritchett Mims, MD, PhD

08:00 AM – 08:20 AM  A Latino Lens: Listening to the Community to Fuel Outreach and Education - Amelie G. Ramirez, DrPH, MPH

08:20 AM – 08:35 AM  OPTIMISE  Oncology - Primary Care Partnership to Improve Comprehensive Survivorship Care - Hoda J. Badr, PhD

08:35 AM – 08:50 AM  Shifting the lens: Engagement of Tribal communities in cancer clinical trials - Andrew Sussman, PhD, MCRP

08:50 AM – 09:05 AM  Reaching Spanish Preferring Populations with Cancer Education and Screening - Susan T. Vadaparampil, PhD, MPH

09:05 AM – 09:30 AM  Panel Discussion 


09:30 AM – 10:00 AM  Break & Exhibits


10:00 AM – 11:00 AM  Session 7: Drug Shortage

Session Chairs: Hannah M. Linden, MD, FACP and Shailender Bhatia, MD

10:00 AM – 10:15 AM  Impossible Choices in Challenging Circumstances: Dealing with Decades of Drug Shortages - Karen Hagerty, MD

10:15 AM – 10:30 AM  Drug shortages: Upstream Factors and Policy Solutions - Mariana Peixoto Socal, MD, PhD

10:30 AM – 11:00 AM  Panel Discussion - W. Thomas Purcell, MD, MBA


11:00 AM – 12:00 PM  Session 8: Oncology Leaders' Approach to Cancer Health Disparities 

Moderator: Amelie G. Ramirez, DrPH, MPH

Panelists: Margaret Foti, PhD, MD (hc); Jorge E. Cortes, MD; Joseph R. Mikhael, MD, MEd, FRCPC, FACP


12:00 PM – 01:00 PM  Lunch & Exhibits


01:00 PM – 02:30 PM  Session 9: Clinical Trials & Research Diversity  

Session Chair: Jorge E. Cortes, MD

01:00 PM – 01:20 PM  Access to Clinical Trials: An Equity and Social Justice Opportunity - Nadine J. Barrett, PhD, MA, MS

01:20 PM – 01:30 PM  Can We Increase Accrual of Minorities in Rural Areas of the Country? A 12 Year Journey - Sharad Ghamande, MD, FACOG

01:30 PM – 01:40 PM  Using Culturally-Tailored Edutainment Videos to Facilitate Recruitment and Decision-Making about Cancer Clinical Trials - Vida Henderson, PhD, PharmD, MPH, MFA

01:40 PM – 01:50 PM  A Simple, Intuitive-Approach for Assessing Clinical Trial Data to Evaluate Outcomes for Under-Represented Patient Populations - Roger M. Stein, PhD

01:50 PM – 02:00 PM  "How can you begin to think about a clinical trial when you can't get food on the table?" A Community Health Worker-led Health Related Social Needs Intervention and the Impact on Clinical Trial Education and Accrual - Manali I. Patel, MD, MPH, MS, FASCO

02:00 PM – 02:30 PM  Panel Discussion - Jerald Radich, MD; Jason A. Mendoza, MD, MPH


02:30 PM – 02:45 PM  Break & Exhibits


02:45 PM – 04:15 PM  Session 10: Global Oncology 

Session Chair: Dan A. Milner, Jr., MD, MSc(EPi), MBA, FASCP

02:45 PM – 03:05 PM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA

03:05 PM – 03:15 PM  New Technologies to Enhance Innate Immunity for the Prevention and Treatment of Cancer in Low Resource Settings - Corey Casper, MD, MPH

03:15 PM – 03:25 PM  Developing Global Cancer Mentorship: A Pilot Experience with Rwanda - Regine Nshimiyimana Maniraho, DNP, BPharm, FNP, AGACNP, AOCNP

03:25 PM – 03:35 PM  Access to Medications: Cases Studies in Solutions - Dan A. Milner, Jr., MD, MSc(EPi), MBA, FASCP

03:35 PM – 03:45 PM  Case Study: Behind the Scenes of 'Streamlined' Care - Joseph Rosales, MD

03:45 PM – 04:15 PM  Panel Discussion - Yogendra P. Singh, MBBS, MD


06:00 PM – 08:30 PM  Binaytara Foundation Gala Dinner


 

DAY 3 - APRIL 28, 2024

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


07:30 AM – 09:00 AM  Session 11: Poster Abstract Session

**This is a non-CME activity**


09:00 AM – 10:30 AM  Session 12: Debate: Is Universal Healthcare A Solution to U.S. Healthcare Disparities? 

Moderators: Manisha Bhattacharya, MD, MBA and Aaron Goodman, MD

Panelists: Karen E. Knudsen, MBA, PhD (CEO of the American Cancer Society); Sen. Manka Dhingra (Deputy Majority Leader of the Washington State Senate); Barbara L. McAneny, MD (Past-President of the American Medical Association); Willie Underwood, III, MD, MSc, MPH (Chair of the American Medical Association Board of Trustees); Rep. Adam Smith (Representative for Washington's 9th Congressional District); Isaac Opole, MD, MBChB, PhD, FACP (President of the American College of Physicians)


10:30 AM – 10:45 AM  Break & Exhibits


10:45 AM – 11:45 AM  Session 13: Oral Abstract Session

Session Chairs: Martha Pritchett Mims, MD, PhD and Darya Kizub, MD

10:45 AM – 10:57 AM  Racial Disparities in GU Cancer Metastasis: A Comprehensive Analysis from 2010-2018 - Abdul Rahman Al Armashi, MD

10:57 AM – 11:09 AM  Remote Contouring Education in Latin America: Longitudinal Effects of Asynchronous Resources with or without Synchronous Virtual Lectures - Michael Dykstra, MD

11:09 AM – 11:21 AM  The SC AMEN Program for Black Men: Providing Education and Navigation to Prostate Cancer Screening with Informed Decision Making - Marvella E. Ford, PhD

11:21 AM – 11:33 AM  Mobile Screening Mammogram Program Serves Vulnerable Population - John L. Bell, MD, FACS, FSSO

11:33 AM – 11:45 AM  An Updated Case Study: Successful Implementation of an Electronic Medical Record System at BTFCC in Nepal - Anish Shah, MD

11:45 AM – 12:00 PM  Abstract Awards

**This is a non-CME activity**


12:00 PM  Adjourn

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States

Attendees and supporters of this meeting can book their hotel room at the Grand Hyatt Seattle at the discounted rate of $209/night + applicable taxes and fees. This rate is based on single occupancy and is valid three days before/after the meeting. The "Cut-Off Date" is 04 April 2024. 

 

 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Hannah Linden, MD FACP

has a financial relationship (Grant Or Contract) with Veru Pharmaceuticals;.
has a financial relationship (Professional Services) with Gillead ;.
has a financial relationship (Grant Or Contract) with Tolmar;.
has a financial relationship (Grant Or Contract) with GE Healthcare ;.
has a financial relationship (Grant Or Contract) with Sanofi;.

Ana Maria Lopez, MD, MPH

has no relevant financial relationships to disclose at this time.
Session Chair(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Exicure;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with 4SC;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.
has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Novartis;.

Jorge Cortes, MD

has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Sun Pharma;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Other) with Pfizer;.

Manish Kohli

has a financial relationship (Travel) with Triomics;.
has a financial relationship (Professional Services) with Tempus Inc;.
has a financial relationship (Professional Services) with Janssen Scientific Affairs, LLC;.
has a financial relationship (Travel) with Apollo Hospital Enterprise Limited;.

Ana Maria Lopez, MD, MPH

has no relevant financial relationships to disclose at this time.

Danny Milner, Jr, MD, MSc, MBA

has no relevant financial relationships to disclose at this time.

Martha Mims

has a financial relationship (Stock) with Biogen IDEC;.
has a financial relationship (Stock) with Amgen;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Aveo;.
has a financial relationship (Grant Or Contract) with Celgene;.

Kamran Mirza, MD PhD

has a financial relationship (Independent contractor) with Astellas Pharma;.

Mark Pegram, MD

has a financial relationship (Employment) with Rain Oncology;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Novartis;.

Gita Suneja, MD, MSHP

has no relevant financial relationships to disclose at this time.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has a financial relationship (Other) with Repare Therapeutics;.
has a financial relationship (Other) with Astrazenca ;.
has a financial relationship (Other) with Astrazeneca ;.
Speaker/Topic Presenter(s)

Michele Andrasik, PhD, EdM, MA, MS

has no relevant financial relationships to disclose at this time.

Nadine Barrett, PhD, MA., MS

has no relevant financial relationships to disclose at this time.

Elle Brooks

has no relevant financial relationships to disclose at this time.

Alan Brownell

has no relevant financial relationships to disclose at this time.

Siddhartha Devarakonda, MBBS, MD

has a financial relationship (Other) with Merus;.
has a financial relationship (Other) with Genetech;.
has a financial relationship (Other) with AZ;.
has a financial relationship (Other) with Jazz;.

Manka Dhingra

has no relevant financial relationships to disclose at this time.

Joseph Finkelstein, MD, PhD, FAMIA, FACMI

has no relevant financial relationships to disclose at this time.

Carrie Fisher, DO

has no relevant financial relationships to disclose at this time.

Margaret Foti

has no relevant financial relationships to disclose at this time.

Nicholas Giustini, MD

has a financial relationship (Other) with Curio Science;.

Stephen Grubbs

has no relevant financial relationships to disclose at this time.

Karen Hagerty

has no relevant financial relationships to disclose at this time.

Carrie Horwitch, MD, MPH

has no relevant financial relationships to disclose at this time.

Irum Khan, MD, MS

has a financial relationship (Professional Services) with BMS;.

Karen Knudsen, MBA, PhD

has no relevant financial relationships to disclose at this time.

Roger M Stein

has no relevant financial relationships to disclose at this time.

Derrick Mapp

has no relevant financial relationships to disclose at this time.

Jason Mendoza, MD, MPH

has no relevant financial relationships to disclose at this time.

Joseph Mikhael, MD, MEd, FRCPC

has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Janssen;.

Regine Nshimiyimana Maniraho, DNP, BPharm, FNP, AGACNP, AOCNP

has no relevant financial relationships to disclose at this time.

Isaac Opole

has no relevant financial relationships to disclose at this time.

Tom purcell, MD, MBA

has no relevant financial relationships to disclose at this time.

Jerald Radich

has a financial relationship (Other) with Cepheid;.
has a financial relationship (Other) with NuProbe;.
has a financial relationship (Other) with Novartis;.

Amelie Ramirez, DrPH

has no relevant financial relationships to disclose at this time.

Adam Smith

has no relevant financial relationships to disclose at this time.

Mariana Socal, MD, PhD, MS, MPP

has no relevant financial relationships to disclose at this time.

Ishwaria Subbiah, MD, MS

has no relevant financial relationships to disclose at this time.

Willie Underwood, III

has no relevant financial relationships to disclose at this time.

Susan Vadaparampil

has no relevant financial relationships to disclose at this time.

Ulka Vaishampayan, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with sanofi;.

Nakita Venus

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Hoda Badr, PhD

has no relevant financial relationships to disclose at this time.

Michael Barr, MD, MBA, MACP, FRCP

has no relevant financial relationships to disclose at this time.

Corey Casper, MD, MPH

has a financial relationship (Grant Or Contract) with Janssen Pharmaceutical;.
has a financial relationship (Grant Or Contract) with ImmunityBio;.
has a financial relationship (Stock Options) with Viracta Therapeutics;.
has a financial relationship (Independent contractor) with Recordati Rare Disease;.

Shelley Fuld Nasso, MPP

has no relevant financial relationships to disclose at this time.

Sharad Ghamande

has a financial relationship (Professional Services) with GSK;.

Vida Henderson

has no relevant financial relationships to disclose at this time.

Barbara McAneny

has no relevant financial relationships to disclose at this time.

Manali Patel, MD, MPH, MS, FASCO

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Yogendra Singh

has no relevant financial relationships to disclose at this time.

Aref Smiley

has no relevant financial relationships to disclose at this time.

Andrew Sussman, PhD, MCRP

has no relevant financial relationships to disclose at this time.
Moderator(s)

Aaron Goodman, MD

has a financial relationship (Professional Services) with Seattle Genetics;.
Planning committee(s)

Manisha Bhattacharya

has no relevant financial relationships to disclose at this time.

Ursa Brown-Glaberman, Associate Professor

has a financial relationship (Independent contractor) with SeaGen;.

Ronan Hsieh, MD, MS

has no relevant financial relationships to disclose at this time.

Darya Kizub, MD

has no relevant financial relationships to disclose at this time.

Umang Swami, MD, MS

has a financial relationship (Other) with Seattle Genetics;.
has a financial relationship (Other) with AstraZeneca ;.
has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Sanofi ;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with ImVax;.
has a financial relationship (Other) with Gilead;.

Srinivas Tantravahi, MBBS; MRCP

has a financial relationship (Professional Services) with CTI BioPharma;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Financial Support) with karyopharm therapeutics;.
has a financial relationship (Professional Services) with MorphoSys;.

Dipesh Uprety, MD, FACP

has a financial relationship (Professional Services) with Daiichi Sankyo, Astrazeneza, Sanofi and Jazz pharmaceuticals;.

Gregory Vidal, MD,PhD

has no relevant financial relationships to disclose at this time.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.

Acknowledgment of Commercial Support

This activity is supported with an independent medical education grant from:

  • AbbVie Inc.

Available Credit

  • 14.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 14.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 14.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 14.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 14.25 Contact Hours.

We would like to thank the following exhibitors and supporters:

 

CompanyExhibit TypeExhibitor Name
AmgenGeneral ExhibitLaurie Thibert
AstrazenecaPremium ExhibitKay Walz
BiocartisGeneral ExhibitCedric Hahn
BiotheranosticsGeneral ExhibitRamzi Karlous
Boehringer IngelheimGeneral ExhibitDavid Waldron
Caris Life SciencesGeneral ExhibitHeidi Sanderson
Daiichi Sankyo, Inc.Premium ExhibitRobert  Gardipee 
EisaiGeneral ExhibitChristie Thompson
ExelixisGeneral ExhibitCarey Miailovich
Foundation MedicineGeneral ExhibitSheri Storey
GileadGeneral ExhibitScott Theiste
GSK OncologyGeneral ExhibitFatima Surani
ImmunocoreGeneral ExhibitPatrick  Short
Incyte CorporationGeneral ExhibitMichael Roh
Janssen Exhibit TableGeneral ExhibitKara Rosso
Kite PharmaceuticalsGeneral ExhibitBrad Arnsmeier
Menarini StemlineGeneral ExhibitDwayne Tyner
MerckGeneral ExhibitHeidi Wilkes
NovartisGeneral ExhibitEric Morales
Novartis OncologyGeneral ExhibitChristine Emert
Pfizer OncologyPremium ExhibitDonna Corsell
PharmaessentiaGeneral ExhibitAlicia Moss
RegeneronGeneral ExhibitManuel Almario
SeagenGeneral ExhibitKelsie Konigsberger
Servier PharmaceuticalsGeneral ExhibitSusan Tokish

 

Price

Cost:
$450.00
Please login or register to take this course.

Register for our Annual Gala! Click the image below: 

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

The registration fee for employees of companies not supporting this meeting is $1500. If your company is a supporter of this meeting, please review the prospectus for pricing.

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot, or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including any pleasantries, introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.